Domenico Penna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Domenico Penna has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
Animesh Pardanani
Divisions of Hematology, Departments of Internal Medicine and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA
2 shared publications- Ayalew Tefferi
Division of Hematology, Department of Medicine Mayo Clinic Rochester Minnesota USA
2 shared publications Curtis A. Hanson
Divisions of Hematopathology, Departments of Internal Medicine and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA
2 shared publicationsFrancesco Merli
Hematology Unit, Azienda Unitа Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy
2 shared publicationsRhett P. Ketterling
Divisions of Laboratory Genetics and Genomics, Departments of Internal Medicine and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA
2 shared publications- Adriano Venditti
Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy
1 shared publication
Latest Publications
- 2 July 2025
- Published by Springer Nature
- p. 311-317
Remote Consultation in Primary Care During Emergencies
- 2 July 2025
- Published by Springer Nature
- p. 311-317
Remote Consultation in Primary Care During Emergencies
- 13 July 2023
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (10) , 1-4
Ruxolitinib: a new first-line strategy in autoimmune myelofibrosis treatment
- 13 July 2023
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (10) , 1-4
Ruxolitinib: a new first-line strategy in autoimmune myelofibrosis treatment
- Open Access
- 11 January 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (1) , 327-338
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
Lymphoma represents a heterogeneous hematological malignancy (HM), which is characterized by severe immunosuppression. Patients diagnosed of coronavirus disease 2019 (COVID-19) during the course of HM have been described to have poor outcome, with only few reports specifically addressing lymphoma patients. Here, we investigated the clinical behavior and clinical parameters of a large multicenter cohort of adult patients with different lymphoma subtypes, with the aim of identifying predictors of death. The study included 856 patients, of whom 619 were enrolled prospectively in a 1-year frame and were followed-up for a median of 66 days (range 1-395). Patients were managed as outpatient (not-admitted cohort, n = 388) or required hospitalization (n = 468), and median age was 63 years (range 19-94). Overall, the 30- and 100-days mortality was 13% (95% confidence interval (CI), 11% to 15%) and 23% (95% CI, 20% to 27%), respectively. Antilymphoma treatment, including anti-CD20 containing regimens, did not impact survival. Patients with Hodgkin’s lymphoma had the more favorable survival, but this was partly related to significantly younger age. The time interval between lymphoma diagnosis and COVID-19 was inversely related to mortality. Multivariable analysis recognized 4 easy-to-use factors (age, gender, lymphocyte, and platelet count) that were associated with risk of death, both in the admitted and in the not-admitted cohort (HR 3.79 and 8.85 for the intermediate- and high-risk group, respectively). Overall, our study shows that patients should not be deprived of the best available treatment of their underlying disease and indicates which patients are at higher risk of death. This study was registered with ClinicalTrials.gov, NCT04352556.
- 11 January 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (1) , 327-338
Open AccessA prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
Lymphoma represents a heterogeneous hematological malignancy (HM), which is characterized by severe immunosuppression. Patients diagnosed of coronavirus disease 2019 (COVID-19) during the course of HM have been described to have poor outcome, with only few reports specifically addressing lymphoma patients. Here, we investigated the clinical behavior and clinical parameters of a large multicenter cohort of adult patients with different lymphoma subtypes, with the aim of identifying predictors of death. The study included 856 patients, of whom 619 were enrolled prospectively in a 1-year frame and were followed-up for a median of 66 days (range 1-395). Patients were managed as outpatient (not-admitted cohort, n = 388) or required hospitalization (n = 468), and median age was 63 years (range 19-94). Overall, the 30- and 100-days mortality was 13% (95% confidence interval (CI), 11% to 15%) and 23% (95% CI, 20% to 27%), respectively. Antilymphoma treatment, including anti-CD20 containing regimens, did not impact survival. Patients with Hodgkin’s lymphoma had the more favorable survival, but this was partly related to significantly younger age. The time interval between lymphoma diagnosis and COVID-19 was inversely related to mortality. Multivariable analysis recognized 4 easy-to-use factors (age, gender, lymphocyte, and platelet count) that were associated with risk of death, both in the admitted and in the not-admitted cohort (HR 3.79 and 8.85 for the intermediate- and high-risk group, respectively). Overall, our study shows that patients should not be deprived of the best available treatment of their underlying disease and indicates which patients are at higher risk of death. This study was registered with ClinicalTrials.gov, NCT04352556.
- Open Access
- 27 October 2020
- Published by Wiley in American Journal of Hematology
- Vol. 96 (2) , E41-E43
SFLT‐1 levels in COVID‐19 patients: Association with outcome and thrombosis
- 27 October 2020
- Published by Wiley in American Journal of Hematology
- Vol. 96 (2) , E41-E43
Open AccessSFLT‐1 levels in COVID‐19 patients: Association with outcome and thrombosis
- 1 May 2019
- Published by Springer Nature in Leukemia
- Vol. 33 (10) , 2522-2553
Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies
- 1 May 2019
- Published by Springer Nature in Leukemia
- Vol. 33 (10) , 2522-2553
Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies
- 5 December 2018
- Published by Wiley in American Journal of Hematology
- Vol. 94 (3) , 286-290
20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long‐lived patients
In the last decade, several prognostic models for primary myelofibrosis (PMF) have been introduced and shown to be effective in predicting overall survival. The main objective for this study was to identify clinical and genetic markers of very long (20+ years) survival in PMF. A total of 1282 patients with PMF were considered (median age 65 years, range 19‐92; 63% males); 26 (2%) patients (median age 51 years, range 28‐71; 38% males) survived their disease for at least 20 years (long‐lived patients) and 626 (49%) patients (median age 68 years, range 27‐92; 66% males) died within 5 years of their diagnosis (short‐lived patients). Multivariable logistic regression analysis identified 7 variables that were associated with survival beyond 20 years: age ≤ 70 years (P = .002); female sex (P = .03); hemoglobin level ≥ 10 g/dL for women and ≥ 11 g/dL for men (P = .03), leukocyte count ≤25 × 109/L (P = .009), platelet count ≥100 × 109/L (P = .002), circulating blasts P = .03) and absence of constitutional symptoms (P = .04). Five‐year mortality was independently predicted by high‐molecular risk mutations (P < .001); unfavorable or very high risk karyotype (P < .001); absence of type 1/like CALR mutation (P < .001); age > 70 years (P < .001); constitutional symptoms (P < .001); hemoglobin level < 10 g/dL for women and < 11 g/dL for men (P < .001); leukocyte count >25 × 109/L (P = .004); and circulating blasts ≥2% (P = .001). This study suggests that genetic risk factors in PMF are associated with early mortality while survival beyond 20 years could be predicted by easily accessible clinical variables, including age, sex, blood counts, and symptoms.
- 5 December 2018
- Published by Wiley in American Journal of Hematology
- Vol. 94 (3) , 286-290
20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long‐lived patients
In the last decade, several prognostic models for primary myelofibrosis (PMF) have been introduced and shown to be effective in predicting overall survival. The main objective for this study was to identify clinical and genetic markers of very long (20+ years) survival in PMF. A total of 1282 patients with PMF were considered (median age 65 years, range 19‐92; 63% males); 26 (2%) patients (median age 51 years, range 28‐71; 38% males) survived their disease for at least 20 years (long‐lived patients) and 626 (49%) patients (median age 68 years, range 27‐92; 66% males) died within 5 years of their diagnosis (short‐lived patients). Multivariable logistic regression analysis identified 7 variables that were associated with survival beyond 20 years: age ≤ 70 years (P = .002); female sex (P = .03); hemoglobin level ≥ 10 g/dL for women and ≥ 11 g/dL for men (P = .03), leukocyte count ≤25 × 109/L (P = .009), platelet count ≥100 × 109/L (P = .002), circulating blasts P = .03) and absence of constitutional symptoms (P = .04). Five‐year mortality was independently predicted by high‐molecular risk mutations (P < .001); unfavorable or very high risk karyotype (P < .001); absence of type 1/like CALR mutation (P < .001); age > 70 years (P < .001); constitutional symptoms (P < .001); hemoglobin level < 10 g/dL for women and < 11 g/dL for men (P < .001); leukocyte count >25 × 109/L (P = .004); and circulating blasts ≥2% (P = .001). This study suggests that genetic risk factors in PMF are associated with early mortality while survival beyond 20 years could be predicted by easily accessible clinical variables, including age, sex, blood counts, and symptoms.